ARWR Annual CAPEX
$141.47 M
-$35.27 M-19.96%
30 September 2024
Summary:
As of January 23, 2025, ARWR annual capital expenditures is $141.47 million, with the most recent change of -$35.27 million (-19.96%) on September 30, 2024. During the last 3 years, it has risen by +$117.90 million (+500.28%). ARWR annual CAPEX is now -19.96% below its all-time high of $176.74 million, reached on September 30, 2023.ARWR CAPEX Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ARWR Quarterly CAPEX
N/A
30 September 2024
Summary:
ARWR quarterly capital expenditures is not available.ARWR Quarterly CAPEX Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ARWR TTM CAPEX
N/A
30 September 2024
Summary:
ARWR TTM capital expenditures is not available.ARWR TTM CAPEX Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ARWR CAPEX Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -20.0% | - | - |
| 3 y3 years | +500.3% | - | - |
| 5 y5 years | +1078.8% | - | - |
ARWR CAPEX High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -20.0% | +500.3% | ||||
| 5 y | 5-year | -20.0% | +1083.6% | ||||
| alltime | all time | -20.0% | >+9999.0% |
Arrowhead Pharmaceuticals CAPEX History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | $141.47 M(-20.0%) | - | - |
| Dec 2023 | - | $68.66 M(+7.4%) | $206.48 M(+16.8%) |
| Sept 2023 | $176.74 M(+234.9%) | $63.91 M(+37.1%) | $176.74 M(+21.4%) |
| June 2023 | - | $46.60 M(+70.6%) | $145.54 M(+34.2%) |
| Mar 2023 | - | $27.31 M(-29.8%) | $108.47 M(+26.3%) |
| Dec 2022 | - | $38.91 M(+19.0%) | $85.91 M(+62.8%) |
| Sept 2022 | $52.78 M(+123.9%) | $32.71 M(+243.0%) | $52.78 M(+86.7%) |
| June 2022 | - | $9.54 M(+100.7%) | $28.27 M(+24.7%) |
| Mar 2022 | - | $4.75 M(-17.8%) | $22.66 M(-9.6%) |
| Dec 2021 | - | $5.78 M(-29.5%) | $25.07 M(+6.4%) |
| Sept 2021 | $23.57 M(+97.2%) | $8.20 M(+108.6%) | $23.57 M(+36.6%) |
| June 2021 | - | $3.93 M(-45.1%) | $17.25 M(+11.6%) |
| Mar 2021 | - | $7.17 M(+67.8%) | $15.46 M(+29.9%) |
| Dec 2020 | - | $4.27 M(+126.6%) | $11.90 M(-0.4%) |
| Sept 2020 | $11.95 M(-0.4%) | $1.89 M(-11.8%) | $11.95 M(-33.2%) |
| June 2020 | - | $2.14 M(-40.8%) | $17.90 M(-5.7%) |
| Mar 2020 | - | $3.61 M(-16.5%) | $18.98 M(+21.8%) |
| Dec 2019 | - | $4.32 M(-44.8%) | $15.58 M(+29.9%) |
| Sept 2019 | $12.00 M(+744.4%) | $7.83 M(+142.9%) | $12.00 M(+145.9%) |
| June 2019 | - | $3.22 M(+1440.1%) | $4.88 M(+163.1%) |
| Mar 2019 | - | $209.30 K(-71.6%) | $1.85 M(-8.4%) |
| Dec 2018 | - | $737.50 K(+3.9%) | $2.02 M(+42.4%) |
| Sept 2018 | $1.42 M(-82.1%) | $709.50 K(+258.2%) | $1.42 M(+73.5%) |
| June 2018 | - | $198.10 K(-47.6%) | $819.20 K(-53.9%) |
| Mar 2018 | - | $378.30 K(+179.4%) | $1.78 M(-35.5%) |
| Dec 2017 | - | $135.40 K(+26.1%) | $2.76 M(-65.2%) |
| Sept 2017 | $7.92 M(+105.1%) | $107.40 K(-90.7%) | $7.92 M(-24.8%) |
| June 2017 | - | $1.16 M(-14.7%) | $10.52 M(+5.1%) |
| Mar 2017 | - | $1.36 M(-74.4%) | $10.01 M(+14.4%) |
| Dec 2016 | - | $5.30 M(+95.3%) | $8.75 M(+126.7%) |
| Sept 2016 | $3.86 M(+95.9%) | $2.71 M(+319.2%) | $3.86 M(+94.7%) |
| June 2016 | - | $647.10 K(+588.4%) | $1.98 M(+22.4%) |
| Mar 2016 | - | $94.00 K(-76.9%) | $1.62 M(-11.1%) |
| Dec 2015 | - | $406.60 K(-51.3%) | $1.82 M(-7.5%) |
| Sept 2015 | $1.97 M(+14.7%) | $835.00 K(+194.4%) | $1.97 M(+23.1%) |
| June 2015 | - | $283.60 K(-4.5%) | $1.60 M(-18.4%) |
| Mar 2015 | - | $297.10 K(-46.5%) | $1.96 M(-9.0%) |
| Dec 2014 | - | $554.90 K(+19.2%) | $2.16 M(+25.5%) |
| Sept 2014 | $1.72 M(+478.4%) | $465.40 K(-27.8%) | $1.72 M(+26.5%) |
| June 2014 | - | $644.20 K(+31.0%) | $1.36 M(+55.4%) |
| Mar 2014 | - | $491.60 K(+323.1%) | $873.20 K(+116.4%) |
| Dec 2013 | - | $116.20 K(+10.5%) | $403.60 K(+36.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2013 | $296.90 K(-38.1%) | $105.20 K(-34.3%) | $296.80 K(+6.6%) |
| June 2013 | - | $160.20 K(+628.2%) | $278.50 K(+19.1%) |
| Mar 2013 | - | $22.00 K(+134.0%) | $233.90 K(-44.3%) |
| Dec 2012 | - | $9400.00(-89.2%) | $419.70 K(-12.5%) |
| Sept 2012 | $479.70 K(+4845.4%) | $86.90 K(-24.8%) | $479.70 K(+22.1%) |
| June 2012 | - | $115.60 K(-44.4%) | $392.80 K(+39.8%) |
| Mar 2012 | - | $207.80 K(+199.4%) | $281.00 K(+255.2%) |
| Dec 2011 | - | $69.40 K(>+9900.0%) | $79.10 K(+715.5%) |
| Sept 2011 | $9700.00(-75.9%) | $0.00(-100.0%) | $9700.00(0.0%) |
| June 2011 | - | $3800.00(-35.6%) | $9700.00(+64.4%) |
| Mar 2011 | - | $5900.00(>+9900.0%) | $5900.00(-85.3%) |
| Sept 2009 | $40.20 K(-94.1%) | $0.00(-100.0%) | $40.20 K(-81.3%) |
| June 2009 | - | $12.10 K(>+9900.0%) | $215.40 K(-39.6%) |
| Mar 2009 | - | $0.00(-100.0%) | $356.60 K(-34.5%) |
| Dec 2008 | - | $28.10 K(-84.0%) | $544.50 K(-20.4%) |
| Sept 2008 | $684.10 K(-9.6%) | $175.20 K(+14.3%) | $684.20 K(-2.5%) |
| June 2008 | - | $153.30 K(-18.4%) | $701.70 K(-26.8%) |
| Mar 2008 | - | $187.90 K(+12.0%) | $959.00 K(+18.6%) |
| Dec 2007 | - | $167.80 K(-12.9%) | $808.70 K(+6.9%) |
| Sept 2007 | $756.40 K(-19.1%) | $192.70 K(-53.1%) | $756.50 K(-13.2%) |
| June 2007 | - | $410.60 K(+992.0%) | $871.60 K(+12.8%) |
| Mar 2007 | - | $37.60 K(-67.5%) | $772.60 K(-19.0%) |
| Dec 2006 | - | $115.60 K(-62.4%) | $953.50 K(+2.0%) |
| Sept 2006 | $934.50 K(+38.9%) | $307.80 K(-1.2%) | $934.50 K(+58.4%) |
| June 2006 | - | $311.60 K(+42.6%) | $590.00 K(+14.2%) |
| Mar 2006 | - | $218.50 K(+126.2%) | $516.80 K(+32.1%) |
| Dec 2005 | - | $96.60 K(-363.2%) | $391.10 K(-41.9%) |
| Sept 2005 | $672.80 K(+1.1%) | -$36.70 K(-115.4%) | $672.70 K(-41.7%) |
| June 2005 | - | $238.40 K(+156.9%) | $1.15 M(+2.2%) |
| Mar 2005 | - | $92.80 K(-75.5%) | $1.13 M(+8.1%) |
| Dec 2004 | - | $378.20 K(-14.8%) | $1.04 M(+56.8%) |
| Sept 2004 | $665.50 K(>+9900.0%) | $443.90 K(+107.9%) | $665.50 K(+200.3%) |
| June 2004 | - | $213.50 K(+2535.8%) | $221.60 K(+2635.8%) |
| Mar 2004 | - | $8100.00(>+9900.0%) | $8100.00(+376.5%) |
| Sept 2003 | $2100.00(+23.5%) | - | - |
| Sept 2002 | $1700.00(+142.9%) | $0.00(0.0%) | $1700.00(0.0%) |
| June 2002 | - | $0.00(-100.0%) | $1700.00(0.0%) |
| Mar 2002 | - | $1700.00(>+9900.0%) | $1700.00(+142.9%) |
| Sept 2000 | $700.00 | $0.00(0.0%) | $700.00(0.0%) |
| June 2000 | - | $0.00(0.0%) | $700.00(0.0%) |
| Mar 2000 | - | $0.00(-100.0%) | $700.00(0.0%) |
| Dec 1999 | - | $700.00 | $700.00 |
FAQ
- What is Arrowhead Pharmaceuticals annual capital expenditures?
- What is the all time high annual CAPEX for Arrowhead Pharmaceuticals?
- What is Arrowhead Pharmaceuticals annual CAPEX year-on-year change?
- What is the all time high quarterly CAPEX for Arrowhead Pharmaceuticals?
- What is the all time high TTM CAPEX for Arrowhead Pharmaceuticals?
What is Arrowhead Pharmaceuticals annual capital expenditures?
The current annual CAPEX of ARWR is $141.47 M
What is the all time high annual CAPEX for Arrowhead Pharmaceuticals?
Arrowhead Pharmaceuticals all-time high annual capital expenditures is $176.74 M
What is Arrowhead Pharmaceuticals annual CAPEX year-on-year change?
Over the past year, ARWR annual capital expenditures has changed by -$35.27 M (-19.96%)
What is the all time high quarterly CAPEX for Arrowhead Pharmaceuticals?
Arrowhead Pharmaceuticals all-time high quarterly capital expenditures is $68.66 M
What is the all time high TTM CAPEX for Arrowhead Pharmaceuticals?
Arrowhead Pharmaceuticals all-time high TTM capital expenditures is $206.48 M